FYARRO™ added to NCCN® Guidelines as the only preferred mTOR inhibitor to treat malignant PEComa PRECISION-1 tumor agnostic study for TSC1 or TSC2 alterations is open for enrollment – LOS ANGELES, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for ... Read More

FYARRO is the first and only approved therapy for adults for the treatment of malignant PEComa, an ultra-rare and aggressive form of sarcoma with a strong female predominance FYARRO launch planned for Q1 2022; Investor call to be held today at 8:30 am ET LOS ANGELES, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) ... Read More

In an Expanded Access Program, advanced malignant PEComa patients who previously progressed on other mTOR inhibitors showed a 25% partial response rate and 63% clinical benefit rate when treated with nab-sirolimus; the subset of patients with TSC1 or TSC2 alterations showed a 44% response rateIn a final analysis from the AMPECT registrational ... Read More

FYARRO™ under review with FDA with a November 26, 2021 PDUFA target date Three key executive appointments made to the roles of Chief Operating Officer, Chief Medical Officer and Chief Financial Officer Appointment of new board member Registrational trial in patients harboring TSC1 and TSC2 inactivating alterations expected to be initiated by the end of ... Read More

LOS ANGELES, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that management will be participating in the upcoming Jefferies London Healthcare Conference and the Piper Sandler Virtual Healthcare Conference.Conference details can be found below.Jefferies London Healthcare ConferenceFormat: ... Read More

LOS ANGELES, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Scott Giacobello, CPA, to the role of Chief Financial Officer (CFO) and Treasurer, effective November 28, 2021.   Most recently, Mr. Giacobello was ... Read More

LOS ANGELES, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Loretta M. Itri, M.D., FACP®, to the role of Chief Medical Officer (CMO). Dr. Itri’s extensive career spans clinical ... Read More